A healthy start to 2024; outlook re-iterated
17/04/24 -"Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ‘temporary’ decline in the ruminant offerings. The ..."
Pages
56
Language
English
Published on
17/04/24
You may also be interested by these reports :
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...
02/05/24
The Q1 results exceeded the street’s expectations, driven by the strong momentum for Novo’s diabetes and obesity offerings. While the management ...
02/05/24
Typically, one would expect defensive attributes in a pharmaceutical stock, however when it comes to the family-controlled Grifols (BUY; Spain), one ...
01/05/24
The Q1 results surpassed expectations, as the performance was largely driven by Vaccines, HIV, Respiratory and Immunology medicines. Moreover, the ...